21 results about "Tromethamine" patented technology

The present invention are co-crystals of Uric Acid with increased solubility with respect to crystals of Uric Acid, suitable for the pharmaceutical use. The invention comprises co-crystals with L-lysine, L-arginine, ethylene diamine, and tromethamine as co-formers, pharmaceutical compositions thereof and their therapeutical use in the prevention or treatment of cerebrovascular diseases.

The invention relates to the technical field of tromethamine synthesis, in particular to a continuous flow synthesis process of tromethamine. Comprising the following steps: adding nitromethane and a solvent A into a container A to obtain a solution A; adding a depolymerizing agent, a solvent B and paraformaldehyde into a container B to obtain a solution B; the first feeding pump and the second feeding pump respectively convey the solution A and the solution B to a micro-channel reactor at the same time for condensation reaction to obtain condensation reaction liquid; transferring the condensation reaction solution to an acidification kettle, and adding a quenching solution for reaction to obtain a quenching reaction solution; diluting the quenching reaction solution, adding a decolorizing agent, and filtering to obtain a decolorizing reaction solution; adding the decolorization reaction liquid and a solvent C into a hydrogenation reaction system by using a circulating pump, and carrying out hydrogenation reaction under the action of hydrogen and a catalyst to obtain hydrogenation reaction liquid; concentrating the hydrogenation reaction liquid to remove the solvent to obtain a tromethamine crude product, and refining the tromethamine crude product to obtain a tromethamine finished product. The method has the effects of low safety risk, continuous and smooth continuous flow pipeline and high product yield and purity.

The present invention relates to a dengue vaccine formulation comprising a tetravalent dengue virus composition comprising a live attenuated dengue virus serotype 1, a live attenuated dengue virus serotype 2, a live attenuated dengue virus serotype 3, and a live attenuated dengue virus serotype 4, at least one non-reducing disaccharide, at least one poloxamer, urea, at least one amino acid having a positively charged side chain at neutral pH, tromethamine, and human serum albumin.

The application provides a low-deuterium water red ginseng and rhodiola compound mask as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The low-deuterium water red ginseng and rhodiola compound mask provided by the application comprises the following raw materials: a red ginseng and rhodiola compound, low-deuterium water, hydroxyethyl cellulose, carbomer-980, carbomer-981, panthenol, 1,2-hexanediol, p-hydroxyphenylacetone, glycerol, dipropylene glycol, beta-glucan, sodium alginate, disodium EDTA, betaine, allantoin, 1,3-butanediol, PEG-40 hydrogenated castor oil and tromethamine; the red ginseng and rhodiola compound is composed of red ginseng extract and rhodiola extract. The low-deuterium water red ginseng and rhodiola compound mask provided by the application has the effects of antioxidation, whitening and anti-photoaging, and can realize synergistic whitening and anti-photoaging.

The invention provides a bio-based efficient film-forming carrier for dissolving and stripping open and closed acnes, which is prepared from the following raw materials in percentage by weight: at least a phase A, a phase B and a phase C. The phase A at least comprises 0.1-1% of microcrystalline cellulose, 0.15-1% of cellulose gum, 3-8% of aureobasidium pullulans polysaccharide, 10-20% of alkaline blackhead exporting liquid, 2-5% of tromethamine and 30-80.25% of water; the phase B at least comprises 1-10% of caprylic / capric triglyceride and 0.5-5% of lauryl glucoside, and the phase C at least comprises 1-15% of cassava starch and 2-5% of 1, 2-pentanediol; the preparation method has the advantages that the reproducible bacterial nano cellulose is used as microcrystalline cellulose, so that a film forming system for dissolving and stripping open and closed acnes is milder and more effective, secondary injury to skin is avoided, and the film forming system is biodegradable, green and sustainable; the invention also provides a preparation method of the bio-based efficient film-forming carrier.

The invention relates to synthesis and application of a carboprost tromethamine chiral epoxy intermediate, and belongs to the technical field of chemical synthesis. The chiral epoxy intermediate compound as shown in the formula (I) is prepared from a compound as shown in the formula (II) and novel chiral sulfonium salt through catalytic asymmetric Corey-Chaykovsky reaction, reaction conditions are simple, and purification is easy. The invention also provides a method for preparing carboprost tromethamine from the compound as shown in the formula (I). The method is simple and convenient to operate, high in asymmetric selectivity and good in yield, the purification difficulty of the carboprost tromethamine is reduced, and the production cost is reduced.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The present invention relates to an aqueous ophthalmic composition comprising spirolactone, cyclodextrin and tromethamine, preferably for topical application to the human eye. The present inventors advantageously dissolve spirolactone in the HP-gamma cyclodextrin excipient at a concentration of 0.1%, which dose has been demonstrated to be effective in the treatment of ocular surface defects. They also have successfully demonstrated that the spirolactone eye drops are stable for up to 9 months at 4 DEG C and achieve its efficacy within at least 6 months, and the formulation is well tolerant after multiple daily instillations within 7 days. In addition, the spirolactone eye drops provided by the invention accelerate healing of corneal wounds of rats, reduce corneal edema and inflammation, enhance epithelial integrity and improve nerve regeneration, and prompt recovery of corneal homeostasis. Thus, the invention also relates to the use of an aqueous ophthalmic composition for the treatment of ocular diseases and disorders.

The present invention relates to a method for preparing crystals of tromethamine or hydrochloride thereof, and crystals of tromethamine or hydrochloride thereof prepared using the preparation method. By lowering the temperature and maintaining same at a constant temperature, large crystal particles of tromethamine or hydrochloride thereof can be obtained uniformly and with high purity.

The present invention relates to a stable aqueous formulation of Leucovorin calcium designed for parenteral administration. This formulation utilizes substituted cyclodextrins, specifically Betadex sulfobutyl ether cyclodextrin (SBE-β-CD) or Hydroxypropyl Beta Cyclodextrin (HP-β-CD), as solubilizers and stabilizers to enhance the drug's aqueous solubility. The inclusion of Tromethamine serves as a buffering agent, maintaining optimal pH levels and ensuring the chemical stability of Leucovorin over an extended shelf life. Importantly, the formulation effectively prevents drug crystallization and particulate matter formation, addressing major stability challenges associated with existing products. The formulation's resilience to freeze-thaw cycles confirm its physical and chemical stability under stress conditions. These advancements not only improve the safety and efficacy of Leucovorin calcium for intravenous administration but also facilitate compliance with regulatory standards, providing a reliable therapeutic option for patients.

The application provides an urapidil hydrochloride injection, and belongs to the field of chemical medicine preparation.The injection comprises urapidil hydrochloride, tromethamine and water for injection, and the pH value of the injection is 6.8-7.5.The application uses tromethamine to improve the pH value of the urapidil hydrochloride injection, greatly enhances the stability of urapidil hydrochloride, and still maintains the good solubility of urapidil hydrochloride at the higher pH value, the clarity of the injection is stable, the performance is excellent, and the product quality is obviously improved.

This invention discloses an ophthalmic ketorolac tromethamine formulation and its preparation method. The ophthalmic ketorolac tromethamine formulation comprises the following components: ketorolac tromethamine, a gel matrix, an osmotic pressure regulator, and a diluent, wherein the gel matrix comprises low-acyl gellan gum and hydroxyethyl cellulose. In vitro release experiments show that the cumulative release rate of this invention reaches over 85% within 8 hours, and the release curve is flat. Compared with existing commercially available eye drops, it significantly reduces the frequency of administration and improves patient compliance. It maintains therapeutic efficacy while reducing the frequency of administration.

The invention provides a single-dose non-steroidal anti-inflammatory drug eye drop. According to the present invention, the compound represented by the formula I is obtained through splitting, and the research results show that the free acid of the compound represented by the formula I has characteristics of low water solubility, poor physical and chemical stability, easy moisture absorption, stickiness, poor fluidity and the like; therefore, various salt forms of the compound shown in the formula I are further researched, tromethamine salt of the compound shown in the formula I is finally selected as an effective component from multiple aspects of physicochemical properties and safety, and the eye drops are prepared through a preparation means to be directly used for eye drop administration, so that the problem that when a prodrug is directly used, the dosage of the tromethamine salt is reduced is effectively solved. And the loxoprofen active metabolite can be used for enriching the application of the loxoprofen active metabolite in antipyretic, analgesic and anti-inflammatory medicines.

The invention discloses a novel medicine for preventing and treating respiratory tract infection as well as a preparation method and application thereof. The effective components of the medicine comprise domiphen and tromethamine. Domiphen and tromethamine do not have a virus killing effect and especially kill new coronal viruses, but the pharmaceutical composition obtained by combining domiphen and tromethamine has a very strong sterilizing effect, also obtains a virus killing effect, can quickly kill viruses and bacterial pathogens within two minutes, can act on respiratory tracts, and has a good effect on killing new coronal viruses, so that the toxic and side effects of the respiratory tracts are reduced, and the toxic and side effects of the respiratory tracts are reduced. The compound has a unique treatment effect on respiratory diseases caused by bacterial and virus infection, and has a wide application prospect in preparation of novel drugs and disinfection products for preventing and treating respiratory infection.

This invention relates to the pharmaceutical field, specifically disclosing the synthesis of a tromethamine linker and its application in drug coupling. The three-load linker uses tromethamine as the parent core, with three hydroxyl groups of tromethamine binding to three loads, and an amino group linked to maleimide, thus constructing a three-load linker. The linker proposed in this invention allows the three loads to be linked to three effector molecules through click chemistry, cyclization reactions, or disulfide bonds; the maleimide is then linked to a targeting ligand to construct a drug coupling agent with three load effector molecules.

Provided are tromethamine salts of 4-chloro-5-[4-(2, 6-dichlorophenyl) sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid, and forms thereof, as well as methods for preparing the tromethamine salts. Also provided are pharmaceutical compositions or veterinary compositions comprising the tromethamine salts and their use for the treatment of a number of diseases.

The utility model provides a reaction device for preparing fosfomycin tromethamine, and particularly relates to the technical field of pharmaceutical production, the reaction device comprises a tank body, a feed port and a discharge port are respectively arranged at the upper end and the lower end of the tank body, an interlayer is arranged outside the tank body, a plurality of partition plates are vertically arranged in the interlayer, and the partition plates divide the interlayer into a plurality of cavities; a first outlet and a second outlet are respectively formed in the lower sides of two adjacent cavities; a first inlet and a second inlet are respectively formed in the upper sides of the two cavities adjacent to the first outlet and the second outlet; in the anticlockwise direction of the first inlet, each cavity is provided with a plurality of first flow guide pipes at intervals, and every two spaced partition plates are connected through the corresponding first flow guide pipe; in the clockwise direction of the second inlet, each cavity is provided with a plurality of second flow guide pipes at intervals, and every two spaced partition plates are connected in a penetrating mode through the corresponding second flow guide pipes. According to the utility model, the heating efficiency can be improved, and the heating uniformity can be improved.

The invention discloses a glycyrrhetinic acid-tromethamine eutectic crystal as well as a preparation method and application thereof in skin care, and belongs to the technical field of biological medicines. The molecular formula of the glycyrrhetinic acid-tromethamine eutectic crystal is [C4H11NO3. 2C30H46O4], the accurate structure of the eutectic crystal is characterized by single crystal X-ray diffraction, and the eutectic crystal forms a basic structural unit through two glycyrrhetinic acid molecules and one tromethamine molecule. The preparation method of the eutectic comprises the following steps: mixing glycyrrhetinic acid and tromethamine according to a molar ratio of (3: 1)-(1: 3), adding an organic solvent such as methanol, ethanol, acetonitrile or isopropanol, stirring and dissolving at 40-60 DEG C, then evaporating to remove the solvent at 40-50 DEG C under reduced pressure, and carrying out vacuum drying to obtain a white eutectic solid. The method is simple in process and suitable for large-scale production. According to the prepared eutectic crystal, the water solubility of glycyrrhetinic acid is remarkably improved, the core problem that glycyrrhetinic acid is prone to layering and precipitation in a water-based system is solved, and the application range and effect of glycyrrhetinic acid are widened.

This invention belongs to the field of pharmaceutical preparation technology, and particularly relates to ketorolac tromethamine biphasic controlled-release tablets and their preparation method. The ketorolac tromethamine biphasic controlled-release tablets include a controlled-release layer and an immediate-release layer. The controlled-release layer includes a double-layer tablet core containing a drug-containing layer and a semi-permeable membrane disposed outside the double-layer tablet core. The semi-permeable membrane allows water molecules to pass through, and has release pores on its side facing the drug-containing layer. After the double-layer tablet core absorbs water molecules passing through the semi-permeable membrane, the ketorolac tromethamine containing the drug-containing layer is released. The immediate-release layer includes a therapeutically effective amount of ketorolac tromethamine and pharmaceutically acceptable immediate-release excipients. This invention combines the effects of immediate release and zero-order release with controlled release, achieving both rapid and long-lasting drug action. It can continuously and stably release the drug within 24 hours, which is beneficial for maintaining a stable blood drug concentration in patients during medication, reducing the frequency of dosing to once daily, and providing a safer, more stable, and longer-lasting analgesic drug formulation for clinical use.

The application provides a hydroxyapatite microsphere for skin injection filling and a preparation method thereof. The preparation method comprises the following steps: step 1: dissolving a calcium source reagent, a phosphorus source reagent and sodium chloride to obtain a high-concentration supersaturated calcium-phosphorus solution; step 2: adding tromethamine into the calcium-phosphorus solution to establish a buffer system, adjusting the pH value of the reaction system to 5.0-9.0, and reacting for 1-24 hours under the condition of constant temperature and low-speed stirring, and then standing for 0.2-4 hours to obtain a hydroxyapatite micro-particle precipitate; step 3: washing the precipitate, and then spray drying to obtain a hydroxyapatite microsphere crude product; and step 4: screening the hydroxyapatite microsphere crude product to obtain the hydroxyapatite microsphere. The obtained hydroxyapatite microsphere product has high sphericity and low crystallinity, and the defects of poor degradability caused by high-temperature sintering and high crystallinity of the microsphere are overcome.